A new research led by Gaurav Sahay of Oregon State University’s College ir Pharmacy was conducted in collaboration with Oregon Health & Science University and the University of Helsinki. In this study, the scientists created and tested over 150 different materials and found a new type of nanoparticle to safely and effectively carry messenger RNA and gene-editing tools to lung cells. This treatment slowed down the growth of lung cancer and helped in improving lung function in studies with mice. The Findings have been published in Nature Communications and the Journal of the American Chemical Society. These studies were funded by the Cystic Fibrosis Foundation, the National Cancer Institute and the National Heart, Lung and Blood Institute.
In studies with mice, this treatment successfully slowed the growth of lung cancer and helped in improving lung function that had been limited by Cystic fibro-sis, a condition caused by one faulty gene. The team of scientists have developed a chemical strategy to build lung-targeting lipids used in the nanocarriers. Also, the materials grom this new drug delivery system could be customized to reach different organs in the body.
“The streamlined synthesis method makes it easier to design future therapies for a wide range of diseases,” Sahay said. “These results demonstrate the power of targeted delivery for genetic medicines. We were able to both activate the immune system to fight cancer and restore function in a genetic lung disease, without harmful side effects.”
Sahay said that our long-term goal is to create safe and more effective treatment by delivering the right genetic tools and to the right place.
The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.
Subscribe to our newsletter or follow us on Facebook or X today to stay informed and never miss an update!